ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Monday, November 18, 2024

10:30AM-12:30PM: Abstract Number: 2288

Interferon Gamma Signaling Is Associated with Development of Extraglandular Manifestations in Sjögren’s Disease

Sjögren's Syndrome – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 2463

Interstitial Lung Disease in Very Early Systemic Sclerosis – a Clinical and Radiological Characterization

Systemic Sclerosis & Related Disorders – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 2271

Intra-Articular Injection of Human Bone Marrow-Derived Mesenchymal Stem Cells in Knee Osteoarthritis: A Randomized, Double-Blind, Controlled Trial

RA – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 1804

Investigating Adaptive Immune Receptor Repertoires by Deep Immune Cell Phenotyping in Preclinical Autoimmunity Development

SLE – Etiology & Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 2441

Investigating Kidney Disease Risks in Systemic Sclerosis (SSc) – Effects of Proton Pump Inhibitors (PPI): Retrospective Analysis

Systemic Sclerosis & Related Disorders – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 2319

Investigating the Association of Serum Metabolites with Psoriatic Arthritis Musculoskeletal Disease Patterns

SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2029

Iron Deficiency in Familial Mediterranean Fever: A Study on 211 Adult Patients from the JIR Cohort

Miscellaneous Rheumatic & Inflammatory Diseases Poster III

10:30AM-12:30PM: Abstract Number: 2378

Is Urinary Protein-creatinine Relation Reliable for Diagnosis or Follow up of Lupus Nephritis?

SLE – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 1902

Ixekizumab for the Treatment of Patients with Spondyloarthritis – Real-world Evidence from the Nationwide Danish Registry, DANBIO

Epidemiology & Public Health Poster III

10:30AM-12:30PM: Abstract Number: 1761

Juvenile Idiopathic Arthritis Genetic Risk Haplotypes: Relevance to Children of African Ancestry

Pediatric Rheumatology – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 1796

Kidney Hematopoietic Stem and Progenitor Cells Contribute to Immune Cell Development and Pathology in Lupus Nephritis

SLE – Etiology & Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 1934

Knee Symptom Phenotyping Incorporating Pain and Function: A Multiple-Trajectory Modeling-Based Study Using Data from the Osteoarthritis Initiative (OAI)

Health Services Research – ACR/ARP Poster III

10:30AM-12:30PM: Abstract Number: 2386

Landscape of Immune Cells and Autoimmunity in Systemic Lupus Erythematosus Patients with Obesity

SLE – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2181

Large Pediatric Cohort with ANCA-associated Vasculitis at a Single Institution: Patient Characteristics, Clinical Course, and Outcomes

Pediatric Rheumatology – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 1815

Leveraging Novel Systemic Sclerosis Disease Signatures to Build a Humanized Drug Discovery Funnel

Systemic Sclerosis & Related Disorders – Basic Science Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].